Pain responder analysis: Use of area under the curve to enhance interpretation of clinical trial results

Pain Practice

Volumn 9, Issue 5, 2009, Pages 348-353

  Cappelleri, Joseph C ^a   Bushmakin, Andrew G ^a   Zlateva, Gergana ^a   Sadosky, Alesia ^a  

^a PFIZER INC   (United States)

Author keywords

Area under the curve; Fibromyalgia; Pain; Responder analysis

Indexed keywords

PLACEBO; PREGABALIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESPONSE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; PAIN; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANALGESICS; AREA UNDER CURVE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 77954836956     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2009.00293.x     Document Type: Article

References (27)

1. Pain Assessment and Management: An Organizational Approach 2000, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, Joint Commission Resources
2. Niv D, Devor M. Chronic pain as a disease in its own right. Pain Pract 2004, 4:179-181.
3. Loeser JD. Pain: disease or dis-ease? The John Bonica Lecture: presented at the Third World Congress of World Institute of Pain, Barcelona 2004. Pain Pract 2005, 5:77-84.
4. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clinic Proc 1999, 74:385-398.
5. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002, 4:299-305.
6. Carville SF, Arendt-Nielsen S, Bliddal H. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67:536-541.
7. Arnold LM, Crofford LJ, Mease PJ. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008, 73:114-120.
8. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008, 8:29.
9. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol 2008, 66:266-275.
10. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything-large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998, 78:209-216.
11. Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 2005, 116:322-331.
12. Dionne RA, Bartoshuk L, Mogil J, Witter J. Individual responder analyses for pain: does one pain scale fit all? Trends Pharmacol Sci 2005, 26:125-130.
13. Farrar JT, Young JR JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
14. Moore RA, Moore O, McQuay HJ, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales. Pain 1997, 69:311-315.
15. Moore RA, Moore OA, Derry S, McQuay HJ. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther 2008, 10:R39.
16. Raskin P, Klaff L, McGill J. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003, 26:2063-2068.
17. Lydick E, Epstein RS, Himmelberger D, White CJ. Area under the curve: a metric for patient subjective responses in episodic diseases. Qual Life Res 1995, 4:41-45.
18. Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist 2005, 10:438-448.
19. Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev 2004, 2. CD004768
20. Toms L, McQuay HJ, Derry S, Moore RA. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev 2008, 4. CD004602
21. Arnold LM, Russell IJ, Diri EW. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9:792-805.
22. Wolfe F, Smythe HA, Yunus MB. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
23. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manag 2006, 31:369-377.
24. Efron B, Tibshirani RJ. An Introduction to the Bootstrap 1993, Boca Raton, FL, Chapman & Hall/CRC
25. SAS/STAT User's Guide 2000, SAS Institute, Version 8, Cary, NC, SAS Institute
26. Dworkin RH, Turk DC, Farrar JT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19.
27. Hellström PM, Hein J, Bytzer P. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2008, 29:198-206.